NextCure, Inc. (NASDAQ:NXTC) and Nordic Bioscience have published a review article in the online journal Frontiers in Immunology, discussing the need for targeting tumor collagen in the extracellular matrix (ECM) to enhance anti-tumor immunity. The review highlights the role of ECM components, specifically collagen, in immune regulation and tumor progression. The publication is part of the ongoing NC410 clinical trial, a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1.